TY - JOUR
T1 - Metastatic Uveal Melanoma
T2 - Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry
AU - Jochems, Anouk
AU - van der Kooij, Monique K.
AU - Fiocco, Marta
AU - Schouwenburg, Maartje G.
AU - Aarts, Maureen J.
AU - van Akkooi, Alexander C.
AU - van den Berkmortel, Franchette W. P. J.
AU - Blank, Christian U.
AU - van den Eertwegh, Alfonsus J. M.
AU - Franken, Margreet G.
AU - de Groot, JanWillem B.
AU - Haanen, John B. A. G.
AU - Hospers, Geke A. P.
AU - Koornstra, Rutger H.
AU - Kruit, Wim H. J.
AU - Louwman, Marieke
AU - Piersma, Djura
AU - van Rijn, Rozemarijn S.
AU - Suijkerbuijk, Karijn P. M.
AU - ten Tije, Albert J.
AU - Vreugdenhil, Gerard
AU - Wouters, Michel W. J. M.
AU - van Zeijl, Michiel C. T.
AU - van der Hoeven, Koos J. M.
AU - Kapiteijn, Ellen
N1 - Funding Information:
Conflicts of Interest: In relation to their contribution to this specific manuscript the authors declare no conflict of interest. Some authors however have consulting/advisory relationships and have received funding for other research projects. A.J. has in the past received travel/ accommodation expenses from Roche BV Netherlands. A.C.v.A. has consulting/advisory relationships with Amgen, BMS, Novartis, MSD and Merck-Pfizer. He has received research funding from Amgen and Novartis and travel, accommodations, and expenses from Amgen and Novartis. C.U.B. has consulting/advisory relationships with BMS, MSD, Roche, Novartis, GSK, Lilly and Pfizer. He has received research funding from Novartis. A.J.M.v.d.E. has consulting/advisory relationships with BMS, Roche, MSD and Novartis. He has received a study grant from R. MargreetG. Franken has received grants from Roche BV Netherlands, Daiichi Sanky, AbbVie, Pamgene and Gilead Sciences. Jan Willem B. de Groot has advisory relationships with BMS, MSD and Roche. J.B.A.G. Haanen has provided consultation, attended advisory boards, and/or provided lectures for MSD, BMS, Roche and Novartis for which NKI received honoraria. His institution has received grant support from BMS and Novartis. G.A.P.H. has consulting/advisory relationships with Roche, MSD, BMS and Novartis. Her institution has received research funding from BMS. RutgerH. Koornstra has received speaker fees from BMS, MSD and Roche. He has advisory relationships with BMS, MSD, Novartis and Roche and has received research grants from BMS and Roche. K.P.M.S. has consulting/advisory relationships with BMS and MSD and has received honoraria from Novartis, Roche and Pierre Fabre (paid to institution). E.K. has consulting/advisory relationships with BMS, Novartis, Roche, Amgen, Pierre Fabre (honoraria paid to institution) and has received research grants from BMS, Novartis.
Funding Information:
Funding: This specific research manuscript received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine programme. From its foundation, the DMTR was sponsored by BMS, GSK (later acquired by Novartis), Roche Nederland B.V. and MSD (from 2015) via the Dutch Institute for Clinical Auditing (DICA).
Funding Information:
This specific research manuscript received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine programme. From its foundation, the DMTR was sponsored by BMS, GSK (later acquired by Novartis), Roche Nederland B.V. and MSD (from 2015) via the Dutch Institute for Clinical Auditing (DICA).
Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/6/26
Y1 - 2019/6/26
N2 - Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63-14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07-4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.
AB - Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63-14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07-4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.
KW - uveal melanoma
KW - metastatic uveal melanoma
KW - survival
KW - treatment strategy
KW - prognostic factor
KW - HEPATIC PERFUSION
KW - PHASE-II
KW - MUTATIONS
KW - IPILIMUMAB
KW - CHEMOTHERAPY
KW - PROGNOSIS
KW - OUTCOMES
KW - SF3B1
KW - GNA11
KW - CARE
U2 - 10.3390/cancers11071007
DO - 10.3390/cancers11071007
M3 - Article
C2 - 31323802
SN - 2072-6694
VL - 11
JO - Cancers
JF - Cancers
IS - 7
M1 - 1007
ER -